Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
September 10, 2014
Blueprint Medicines Discovers Novel Cancer Drug Targets
- Findings and … [Read More...]
September 8, 2014
Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular … [Read More...]